A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Name: A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Published: 2015
License: Public Domain

Eli Lilly and Company · 2015

ClinicalTrials.gov · Datasets · License: Public Domain · 2015

Open Source ↗

angiogenesis carcinoma non-small-cell-lung-cancer

gastric adenocarcinoma, adenocarcinoma of the gastroesophageal junction, non-small cell lung cancer, carcinoma, transitional cell, biliary tract cancer, immuno-oncology, vascular endothelial growth factor (vegf), angiogenesis, pd-1, carcinoma of the bladder, carcinoma of the urethra, carcinoma of the ureter

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 911288
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.